Combination of Short-Term ADT, Radiation Therapy Benefits Early-Stage Prostate Cancer Patients

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
Short-term hormone therapy (androgen deprivation therapy, or ADT) administered in combination with radiation therapy for men with early-stage prostate cancer increases their chance of living longer and not dying from the disease, compared with that of those who receive the same radiation therapy alone, according to a Radiation Therapy Oncology Group (RTOG) study published in the July 14 issue of the New England Journal of Medicine. The largest randomized trial of its kind, the study enrolled nearly 2,000 men at low and intermediate risk of prostate cancer progression and followed their health status for more than nine years, from October 1994 to April 2001, at 212 centers in the U.S. and Canada. All study participants had early, localized, PSA-diagnosed tumors with PSA levels of 10 to